

Haematologica
HAEMATOL/2017/176347
Version 3

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Konstantin Byrgazov, Chantal Blanche Lucini, Peter Valent, Oliver Hantschel, and Thomas Lion

Disclosures: This work was supported by the Austrian Science Fund (FWF), SFB Grants F4705-B20 (T.L.) and F4704-B20 (P.V.). The authors declare no conflict of interests.

Contributions: K.B. developed the research line, cloned single and compound mutations of BCR-ABL1, established the cell cultures, performed drug sensitivity tests and clonal co-evolution experiments, wrote the manuscript; C.B.L. cloned the constructs for co-evolution experiments and performed drug sensitivity tests; P.V. discussed the data and revised the manuscript; O.H. provided the list of compound mutations for further studies, discussed the data and revised the manuscript; T.L. developed the research line and wrote the manuscript. All the authors read and approved the final article.